Publications by authors named "M P Morisseau"
Article Synopsis
- The study aimed to investigate the relationship between the immune microenvironment and survival outcomes in patients with vulvovaginal melanoma.
- It involved a retrospective analysis of 42 patients, examining tumor-infiltrating lymphocytes and genetic mutations, with significant findings on immune cell presence related to better disease-free survival.
- The researchers concluded that specific types of tumor-infiltrating lymphocytes could indicate disease progression and response to treatments, suggesting the need for further multicenter studies to confirm these results.
Article Synopsis
- * It introduces modern analysis techniques that factor in the timing and recurrence of immune-related AEs (irAEs) in cancer patients treated with immune checkpoint inhibitors, based on the MOTIVATE prospective study findings.
- * Results showed variations in the prevalence and timing of irAEs between melanoma and non-small cell lung cancer (NSCLC) patients, leading to more comprehensive safety assessments that can guide clinical and regulatory decisions.
Article Synopsis
- - The study investigates the effectiveness of high-dose-rate (HDR) brachytherapy as an alternative treatment for localized cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) on the face, focusing on local control, survival rates, and quality of life from 2015 to 2021.
- - Out of 67 patients treated, with a majority having early-stage tumors, the local control rate after three years was 87.05%, and most patients experienced only mild side effects like acute radio-mucositis.
- - Quality of life feedback from patients indicated that 77.8% would recommend HDR brachytherapy, underscoring its effectiveness, tolerance, and positive impact on functional outcomes in
Background: Current guidelines recommend that patients with HER2-low metastatic breast cancer (MBC) receive sequentially two antibody-drug conjugates (ADCs): Sacituzumab Govitecan (SG) and Trastuzumab Deruxtecan (T-DXd), despite a similar payload. However, the effectiveness of one after another is unknown.
Methods: ADC-Low is a multicentre, retrospective study evaluating the efficacy of SG and T-DXd, one after another, with or without intermediary lines of chemotherapy, in patients with HER2-low MBC.
Background: Data suggest an association between positron emission tomography/CT (PET/CT) metabolic metrics and tumor microenvironment in several malignancies, and a potential role of PET/CT to monitor response to immunotherapy.
Objective: To evaluate the correlation between tumor loco-regional extension and tumor-infiltrating lymphocyte infiltration in locally advanced cervical cancer prior to concurrent chemo-radiotherapy.The secondary objective was to assess the association between tumor-infiltrating lymphocytes and PET/CT metabolic metrics.